NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 903.3 DKK | -1.05% |
|
-0.73% | +29.39% |
| 10:54am | Roche: share price stands out, Deutsche Bank in support | CF |
| 16/05 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
Presenter SpeechRichard Vosser (Analysts)All right. Welcome, everyone, to Novo's Q1 roadshow. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.39% | 593B | |
| +32.07% | 694B | |
| -1.51% | 371B | |
| +19.97% | 331B | |
| +7.18% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.39% | 169B | |
| -0.71% | 164B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S, Q1 2022 Earnings Call, May 05, 2022
